

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound from 42-20 to 50 nucleobases in length targeted to a nucleic acid molecule encoding growth hormone receptor, wherein said compound comprises ~~an at least 8 consecutive nucleobase portion of the nucleobase sequence~~ of SEQ ID NO: 19; and wherein said compound is at least ~~95_80%~~ complementary ~~with-to~~ SEQ ID NO: 4 as measured over the entire[[ty]] length of said compound.

2-3. (Canceled).

4. (Previously Presented) The compound according to claim 1 wherein said compound is an oligonucleotide.

5. (Currently Amended) The compound according to claim 4, wherein ~~in which~~ the oligonucleotide is a single-stranded oligonucleotide.

6. (Currently Amended) The compound according to claim 4, wherein ~~in which~~ the oligonucleotide is a DNA oligonucleotide.

7. (Currently Amended) The compound according to claim 4, wherein ~~in which~~ the oligonucleotide is a RNA oligonucleotide.

8. (Canceled).

9. (Previously Presented) The compound according to claim 1, wherein said compound is a short interfering RNA (siRNA) molecule.

10-12. (Canceled).

13. (Currently Amended) The compound according to claim 1, wherein said compound is comprising-100% complementary[[ity]] ~~with-to~~ SEQ ID NO: 4 as measured over the entire[[ty]] length of said compound.

14-19. (Canceled)

20. (Currently Amended) The compound according to claim 1, wherein said compound comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified nucleobase, and a modified sugar, ~~or combination thereof~~.

21. (Currently Amended) The compound according to claim 20, wherein said compound comprises at least one ~~the~~ modified sugar is selected from the group consisting of a 2'-O-(2-methoxyethyl), and a 4'-(CH₂)_n-O-2' bridge, wherein n is 1 or 2.

22. (Previously Presented) The compound according to claim 20 wherein said compound comprises at least one phosphorothioate internucleoside linkage.

23. (Previously Presented) The compound according to claim 20 wherein said compound comprises at least one 5-methylcytosine.

24-45. (Canceled)

46. (Currently Amended) The compound of claim 1, wherein said compound is an antisense oligonucleotide 20 to 50 nucleobases in length comprising the nucleobase sequence of SEQ ID NO: 19, wherein said antisense oligonucleotide 20 to 50 nucleobases in length comprises a ten deoxynucleotide region flanked on both the 5' end and the 3' end of said ten deoxynucleotide region with at least five 2'-O-(2-methoxyethyl) nucleotides, wherein each internucleoside linkage in said antisense oligonucleotide is a phosphorothioate linkage and wherein each cytosine in said antisense oligonucleotide is a 5-methylcytosine.

47. (Previously Presented) A pharmaceutical composition comprising the antisense oligonucleotide of claim 46 and an ingredient selected from the group consisting of a pharmaceutically acceptable carrier, diluent, penetration enhancer, excipient and combinations thereof.

48-49. (Canceled).

50. (Currently Amended) ~~A~~The compound of claim 1, wherein said compound is from 15-20 to 30 nucleobases in length targeted to a nucleic acid molecule encoding growth hormone receptor, wherein said compound comprises at least 8 consecutive nucleobases from SEQ ID NO: 19 and is at least 80% complementary with SEQ ID NO: 4 as measured over the entire length of said compound.

51. (Canceled).

52. (Currently Amended) The compound of claim 50, comprising at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar, and a modified nucleobase, ~~or combination thereof~~.

53. (Currently Amended) The compound of claim 52, having at least one modified sugar selected from the group consisting of a 2'-O-(2-methoxyethyl) sugar moiety and a 4'-(CH₂)_n-O-2' bridge, wherein n is 1 or 2.

54. (Previously Presented) The compound of claim 52 having at least one phosphorothioate internucleoside linkage.

55. (Previously Presented) The compound of claim 52 having at least one 5-methylcytosine.

56. (Currently Amended) The compound of claim 52, wherein said compound that is a pharmaceutically acceptable salt.

57. (Currently Amended) The compound of claim 50, wherein said compound that is a pharmaceutically acceptable salt.

58. (Currently Amended) The compound of claim 50, wherein said compound is at least 95% complementary ~~complementary~~ to SEQ ID NO: 4 as measured over the entire length of said compound.

59. (Currently Amended) The compound of claim 50, wherein said compound is 100% complementary ~~complementary~~ to SEQ ID NO: 4 as measured over the entire length of said compound.

60. (Previously Presented) The compound of claim 46, wherein said compound is 20 nucleotides in length.

61. (Currently Amended) The compound of claim 50, wherein said compound is at least 90% complementary ~~with~~ to SEQ ID NO: 4 as measured over the entire length of said compound.

62-65. (Canceled).

66. (Previously Presented) The compound of claim 59, wherein said compound is an oligonucleotide.

67. (Previously Presented) The compound of claim 66, comprising at least one 2'-O-(2-methoxyethyl) nucleotide, at least one phosphorothioate internucleoside linkage, and at least one 5-methylcytosine.

68. (Currently Amended) The compound of claim 67, wherein said compound comprises:

a region of deoxynucleotides flanked on both the 5' end and the 3' end[[s]] of said deoxynucleotide region with at least one 2'-O-(2-methoxyethyl) nucleotide;

wherein each internucleoside linkages of said compound is a phosphorothioate internucleoside linkage;

and wherein each cytosine of said compound is a 5-methylcytosine.

69. (Canceled).

70. (Currently Amended) A compound comprising a modified oligonucleotide consisting of 20 linked nucleosides and having a nucleobase sequence consisting of the nucleobase sequence recited in SEQ ID NO: 19, wherein said modified oligonucleotide consists of a ten deoxynucleotide region flanked on both the 5' end and the 3' end[[s]] of said ten deoxynucleotide region with five 2'-O-(2-methoxyethyl) nucleotides, wherein each internucleoside linkage in said modified oligonucleotide is a phosphorothioate linkage and each cytosine in said modified oligonucleotide is a 5-methylcytosine.

71. (Previously Presented) A composition comprising the compound of claim 70 or a salt thereof and a pharmaceutically acceptable carrier or diluent.

72. (Previously Presented) The composition of claim 71, wherein the salt is a sodium salt.

73. (Currently Amended) The compound of claim 1, wherein said compound comprises:

a region of deoxynucleotides flanked on both the 5' end and the 3' end[[s]] of said deoxynucleotide region with at least one 2'-O-(2-methoxyethyl) nucleotide;

wherein each internucleoside linkage of said compound is a phosphorothioate internucleoside linkage;

and wherein each cytosine of said compound is a 5-methylcytosine.

74. (Previously Presented) The compound of claim 4, wherein said compound is 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleobases in length.

75. (New) The compound of claim 1, wherein said compound is at least 90% complementary to SEQ ID NO: 4 as measured over the entire length of said compound.

76. (New) The compound of claim 1, wherein said compound is at least 95% complementary to SEQ ID NO: 4 as measured over the entire length of said compound.

77. (New) The compound of claim 1, wherein said compound is 100% complementary to SEQ ID NO: 4 as measured over the entire length of said compound.